HyTest | SARS-Cov-2重組抗原和血清學標記產品介紹

HyTest | SARS-Cov-2重組抗原和血清學標記產品介紹



HyTest的新冠病毒(SARS-Cov-2)Spike RBD重組抗原開發正邁入完成的最後一哩路,該抗原在哺乳動物細胞中產生,可用於血清學檢測。


HyTest COVID-19 News






We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen. The antigen is produced in mammalian cells and could be used in serology assays. 


The product is lyophilized, which makes its shipment and storage convenient.


We now have a limited amount of R&D samples available.










While IgA has gained little attention by developers of SARS-Cov-2 antibody tests, recent publications suggest that including it in serology assays could improve the sensitivity of the tests.


It was shown that IgA antibodies can be detected earlier than IgM or IgG antibodies. Also, IgA (and IgG) antibodies seem to positively correlate with the severity of the disease.





Webinar Video COVID-19: Biomarkers to Distinguish Severity and Prognosis  


By watching this webinar, you will learn about:


–  the use of nucleic acid testing and serological testing for diagnostics of COVID-19, as well as the benefits and limitations of these methods for COVID-19 diagnostics

–  the effects of SARS-CoV-2 on the cardiovascular system

–  the role of cardiac and inflammatory biomarkers in distinguishing the severity and prognosis of COVID-19 






LINE 線上諮詢



error: Content is protected !!